

**Boehringer Ingelheim announces a pre-signing with Dopharma  
for the acquisition of its production site in Saint-Herblon,  
France**

**15 October 2018** - The proposed sale of the Saint-Herblon (France, Loire-Atlantique) production site had been announced in October 2017 following the presentation of **Boehringer Ingelheim Animal Health** strategic orientations. On this occasion, the group had affirmed its strategy to focus on advanced and preventive animal healthcare. Saint-Herblon mainly produces generics and antibiotics for livestock, under the **Coophavet** brand.

**Boehringer Ingelheim** had identified a strong buyer in order to offer a sustainable future for the site and its employees. The selected buyer is an independent and family-owned Dutch company that develops, produces and distributes veterinary products 100% dedicated to livestock.

**Dopharma** is a growing player on the market, already distributing in more than 50 countries. It employs 165 people and has 2 production sites in Europe. Saint-Herblon and **Coophavet** will therefore represent a major part of its activity.

*"With the acquisition of the Saint-Herblon production site, we are establishing our presence in France and we will benefit from an addition to our portfolio and distribution possibilities that is fully in line with our strategy. We intend to capitalize on employees' know-how to keep growing together,"* explains **Wijnand de Bruijn**, General Manager External Affairs and President of **Animal Health Europe**.

*"I am convinced that this project will offer a solid foundation for the future to the site and its employees. Indeed, we will collaborate with **Dopharma Saint-Herblon** that will produce some of our specialized products during the coming years."* adds **Erick Lelouche**, President of **Boehringer Ingelheim Animal Health** in France.

The sale should be completed by the end of Q1 2019, after the legal and consultation process is completed.

**About **Boehringer Ingelheim****

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company **Boehringer Ingelheim**. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients' lives. In animal health, **Boehringer Ingelheim** stands for advanced prevention.

Family-owned since it was established in 1885, **Boehringer Ingelheim** is one of the pharmaceutical industry's top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, **Boehringer Ingelheim** achieved net sales of nearly 18.1 billion

euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on [www.boehringer-ingelheim.com](http://www.boehringer-ingelheim.com) or in our annual report: <http://annualreport.boehringer-ingelheim.com>

#### **About Boehringer Ingelheim Animal Health**

Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal wellbeing through our large portfolio of advanced, preventive healthcare products and services. With net sales of 3.9 billion euros and around 10,000 employees worldwide, we are present in more than 150 markets.

#### **About Dopharma**

Dopharma is a family owned veterinary pharmaceutical company with its headquarters in the Netherlands. Dopharma delivers high quality veterinary pharmaceuticals for livestock since its establishment in 1969. Started as a one-man business and grown into a company with 6 production lines and 165 employees. Dopharma's products are sold in over 50 countries by 4 local subsidiaries and approximately 40 distribution partners. Dopharma produces antibacterial, antiparasitic and anti-inflammatory products as well as hormone preparations, corrective preparations and complementary feed. In 2017 Dopharma has acquired a majority share in RIPAC-Labor specialized in the development and production of autogenous vaccines. Together we work towards clever and sophisticated solutions in order to achieve the best results possible.

#### **Media contacts**

##### **Boehringer Ingelheim France**

###### **Nicolas Meynaud**

Communication Boehringer Ingelheim France  
Mobile: +33 675 89 75 19  
[nicolas.meynaud@boehringer-ingelheim.com](mailto:nicolas.meynaud@boehringer-ingelheim.com)

##### **Dopharma**

###### **Erik Pieke**

Director Marketing & Strategy  
Mobile: +31653820394  
[e.pieke@dopharma.com](mailto:e.pieke@dopharma.com)